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Gain-of-function mutations of KIT are pathognomonic in sporadic gastrointestinal stromal tumors (GISTs). Several microRNAs
have been shown to be dysregulated in GISTs and impact KIT expression. Little is known though on KIT-independent targets
of KIT-regulating mRNAs. We sought to investigate how miR-494 inhibits GIST proliferation and to identify novel target gene.
We used microarray-based gene expression analyses to identify pathways and target genes affected by miR-494. The expres-
sional relationship between survivin and miR-494 was determined in 35 GIST tissues. Cell proliferation assay, FACS analysis,
colony formation assay, promoter assays and chromatin immunoprecipitation (ChiP) were performed to clarify the roles of sur-
vivin in GIST progression. Gene expression microarray analysis revealed that miR-494 inhibited GISTs by affecting multiple
genes in the cell cycle pathway. Survivin (BIRC5) was a key target of miR-494, and its expression showed an inverse correla-
tion with miR-494 expression in 35 GIST tissues (Pearson’s correlation coefficient, r520.418, p50.012). Downregulation of
survivin inhibited proliferation and colony formation, and resulted in cell cycle alteration. Induced survivin overexpression
relieved miR-494-mediated inhibition of GIST progression. Targeting PI3K effectively suppressed proliferation of GISTs with
downregulation of survivin. Survivin also regulated KIT expression at the transcription level. Immunohistochemical analysis
using 113 GISTs revealed that survivin expression was significantly correlated with overall survival of GIST patients
(p50.004). Our findings indicated that miR-494 synergistically suppressed GISTs by concomitantly targeting survivin and KIT.
Introduction
Gastrointestinal stromal tumors (GISTs) are the most com-
mon mesenchymal tumors of the gastrointestinal tract. Mutu-
ally exclusive single-gene mutations in KIT (75%) and
PDGFRA (10%) are thought to be the initiating genomic
event in the oncogenic progression of sporadic GISTs.1–4 By
contrast, GISTs arising in the absence of mutations in KIT or
PDGFRA are attributed to functional defects in the mito-
chondrial succinate dehydrogenase (SDH) complex, which is
composed of subunits SDHA, SDHB, SDHC and SDHD.5
These SDH-deﬁcient GISTs harbor mutations in one of the
four SDH isoforms.5 KIT remains the major oncogenic driver
even in patients with widespread metastatic disease, which
explains the success of speciﬁc KIT-inhibitors. Imatinib
blocks autophosphorylation of KIT as well as KIT-dependent
signaling such as RAS/RAF/MAPK and PI3K pathways,
which subsequently inhibits proliferation or induces apopto-
sis.6 While imatinib shows long lasting remissions, most
patients eventually progress with only a minority of patients
permanently responding to treatment.7 Notably, KIT remains
the major driver of the disease even after progression on
imatinib as patients develop secondary resistance mutations
in the kinase domain of KIT.8 As many patients develop
multiple different resistant clones at the same time, effective
pharmacological inhibition remains an obstacle in clinical
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practice.9 Thus, current salvage therapies exhibit only moder-
ate disease control rates and patients failing imatinib are
faced with a poor outcome.10,11 Novel approaches that inhibit
KIT—regardless of secondary mutations—as well as the iden-
tiﬁcation of additional targetable driver genes in GISTs are
required.
Although a wide range of therapies that inhibit KIT at the
protein level are now available, therapeutic approaches
enabling mRNA-level regulation of KIT expression have been
rarely reported.10,12 Loss of chromosome 14q is a frequent
cytogenetic event (80% in gastric GISTs).13 Interestingly, a
cluster of forty-seven miRNAs is located on 14q32.2 and
32.31 and miRNAs in this region are frequently downregu-
lated or silenced in several types of cancers, suggesting a
tumor-suppressor role for the miRNAs in this cluster.14,15
Only few functional studies have been performed to elucidate
the role of these miRNAs in GISTs. Of note, microRNAs
that selectively regulate gene expression have been shown as
efﬁcient KIT suppressors.16 MiR-17/20a, miR-193a, miR-218,
miR-221, miR-222 and miR-494 target KIT mRNAs; their
expression inversely correlates with the expression of KIT in
leukemia and GISTs.17–21 MiR-494 downregulates KIT
expression by binding two different sites in the 30-UTR of
KIT mRNAs in GISTs, inhibit proliferation, and eventually
induce GIST cell apoptosis.20 Low expression of miR-494
that occurs with the frequent loss of the 14q chromosome
(approximately 70% of GISTs) may therefore contribute to
high expression levels of KIT and therefore contribute to
oncogenic dependency on KIT as well as GISTs tumorigene-
sis.16 A single microRNA theoretically binds to approximately
100 target genes, and some target genes show reduced
microRNA-mediated protein output.22,23 Only a limited num-
ber of the target genes form a gene set that is functionally
sensitive to a speciﬁc miRNA.22,24 Many target genes of miR-
494 (e.g., PTEN, CDC20 and FGFR2) have been identiﬁed in
cholangiocarcinoma, glioblastoma and ovarian cancers.25–27
However, KIT is the only critical target gene of miR-494 that
has been found in GISTs.20 A better understanding of target
genes of, and pathways regulated by, miR-494 in these
tumors may therefore pave the way to novel targets that
maintain the oncogenic phenotype in GISTs.
We used a microarray approach to determine mechanisms
of miR-494-mediated inhibition of GISTs and found that the
cell cycle pathway was the most signiﬁcantly affected by
miR-494. We further found that survivin (encoded by BIRC5)
was directly targeted by miR-494, and was variably expressed
in most GIST tissues. Our ﬁndings demonstrated that survi-
vin had key roles in PI3K pathway dependent GIST progres-
sion and transcriptional regulation of KIT expression.
Survivin expression also had a signiﬁcant relationship with
some important clinicopathological factors in a cohort of
GIST patients. Taken together, these ﬁndings revealed novel
functions of miR-494 and provide a therapeutic rationale for
its application to GIST treatment.
Material and Methods
Cell lines and culture, dual luciferase assay, quantitative
(q)PCR, western blotting and immunofluorescence, colony
formation assay and cell-cycle and apoptosis analysis
Cell lines and culture, dual luciferase assay, quantitative
(q)PCR, western blotting and immunoﬂuorescence, colony
formation assay and cell-cycle and apoptosis analysis are
described in Supporting Information (Material and Methods).
Tissue samples
Thirty-ﬁve fresh frozen and 113 formalin-ﬁxed parafﬁn-
embedded GIST tissue samples were obtained from the
archives of the Department of Pathology, Yonsei University
(Seoul, Korea) and from the Liver Cancer Specimen Bank of
the National Research Resource Bank Program of the Korea
Science and Engineering Foundation of the Ministry of Science
and Technology. The Institutional Review Board of the Yonsei
University of College of Medicine approved the use of these tis-
sues for research purposes. All specimens were obtained from
patients who had undergone surgical resection at Severance
Hospital between 2003 and 2013. None of the patient tissue
samples were used in other studies, and no results obtained
from these samples have been published elsewhere. Fresh fro-
zen GIST tissues were used for the expression analysis of KIT,
miR-494 and survivin using qPCR and western blotting. One
hundred and thirteen formalin-ﬁxed parafﬁn-embedded GIST
tissues were used for immunohistochemistry.
Cell proliferation assay
The GIST430 and GIST882 cells were transfected with siNC,
miR-494 or siSurvivin. The cells were harvested and manu-
ally counted at 3- and 5-day post-transfection. Proliferation
and signaling pathway alteration were also evaluated in
GIST430 and GIST882 cells with or without kinase inhibitors.
The following kinase inhibitors were used in the study:
PD0325901 (Sigma, St. Louis, MO, USA), an MEK inhibitor;
What’s new?
Gain-of-function mutations of KIT are pathognomonic in sporadic gastrointestinal stromal tumors (GISTs). Several microRNAs
have also been shown to be dysregulated in GISTs and impact KIT expression. However, still little is known on KIT-
independent targets of KIT-regulating mRNAs. Here, the authors report that miR-494 induces alteration of the cell cycle path-
ways in GISTs by downregulating survivin, which functions as a transcription factor of KIT, accompanying effective blockade of
the PI3K pathway that both KIT and survivin belong to. Based on these findings, miR-494 may play important roles during
GIST tumorigenesis and be used as a potent agent to treat GISTs.
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ZSTK474 (Cell Signaling Technology, Beverly, MA, USA), a
PI3K inhibitor and MK-2206 2HCl (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), an AKT inhibitor.
Construction of expression vectors, miRNA mimics, siRNA
and transfection
Survivin expression vectors were generated by cloning the cod-
ing region (with and without the 30-UTR region) into a plasmid
cytomegalovirus (pCMV, Sigma) vector with a 33-FLAG tag.
The mutant KIT expression vector was described elsewhere.28
To construct vectors used for target validation and the pro-
moter assays, Target Scan-predicted 30-UTR regions of survivin,
FOXM1, DNMT3B and CKS1B (NCBI reference sequences:
NM_001168, NM_202002, NM_001207055 and NM_001826)
were conjugated with the Renilla luciferase expression vector
(pRL vector, Promega, Madison, WI, USA). The KIT promoter
regions (including putative survivin binding sites) were conju-
gated with the Fireﬂy luciferase expression vector (pGL vector,
Promega). MiRNA mimics (miR-221, miR-193a and miR-494),
a miR-494 inhibitor and siRNA (siSurvivin) were purchased
from Dharmacon (Dharmacon, Lafayette, CO USA). Nontar-
geting siRNA (siNC), siRNA (siKIT) were purchased from
Bioneer (Bioneer Corporation, Daejeon, South Korea). All
transfection experiments were performed using lipofectamine
3000 (Invitrogen, Carlsbad, CA, USA). Primers used in our
study are listed in Supporting Information Table S1.
Chromatin immunoprecipitation (ChiP)
To determine whether survivin binds to the KIT promoter
region, ChiP assays were performed using a Simple ChiP
Enzymatic Chromatin IP kit (Cell Signaling Technology)
according to the manufacturer’s instructions. DNA and pro-
teins in GIST430 cells were cross-linked by treatment with
1% formaldehyde. Chromatin was digested using micrococcal
nuclease and sonication, and optimal fragmentation was con-
ﬁrmed. Immunoprecipitation was then performed using anti-
survivin antibody (Novus Biologicals, Littleton, CO, USA),
anti-histone H3 antibody (positive control) and normal rab-
bit IgG (negative control). The anti-histone H3 antibody and
normal rabbit IgG were provided in the ChiP assay kit.
Enriched DNA was analyzed using semi-qPCR. RPL30 exon
3 control primers (for the positive control sample) were also
provided in the ChiP assay kit. The primers used to amplify
the enriched KIT promoter region are listed in Supporting
Information Table S1.
Immunohistochemistry and statistical analysis
Tissue microarray sections (4-lm thickness) were obtained
from parafﬁn-embedded GIST tissues from 113 patients.
Serial sections were manually stained with antibody against
survivin (1:1,200, Cell Signaling Technology). Survivin
expression was evaluated based on H-scores, which were cal-
culated using both expression intensity and proportion of
expression in tumors according to the following equation:
(1 3 [% cells 11]1 2 3 [% cells 21]1 3 3 [% cells 31]),
where 1, 2 and 3 represent the relative intensity of survivin
expression. H-scores were used to group patients according
to strong, moderate or weak survivin expression. Fisher’s
exact test, the v2-test, Kaplan–Meier survival analysis, Pear-
son’s correlation analysis and Cox proportional hazards anal-
ysis were used to analyze the relationships between survivin
expression and clinicopathological parameters (SPSS software,
SPSS, Inc., Chicago, IL, USA). DAVID software (Database for
Annotation, Visualization an Integrated Discovery, v6.7;
http://david.abcc.ncifcrf.gov) and BINGO 2.3 plugin for Cyto-
scape software (http://www.psb.ugent.be/cbd/papers/BiNGO/
Home.html) were used for pathway and gene ontology analy-
sis. Putative survivin binding regions of KIT gene were
selected using MethPrimer (http://www.urogene.org/cgi-bin/
methprimer/methprimer.cgi).
Microarray and data accession
Total RNA was extracted using an RNA Isolation kit (GE
Healthcare Life Sciences, Logan, UT, USA) and then pooled
for DNA microarray hybridization. Biotin-labeled cRNA tar-
gets were synthesized using 1.5 lg of total RNA, and an
IlluminaVR TotalPrep RNA Ampliﬁcation kit (Illumina, San
Diego, CA, USA) was used to synthesize double-stranded
cDNA. Biotin-UTP-labeled antisense RNA was transcribed in
vitro using an Ambion MEGAscript kit (Ambion Life Tech-
nologies, Carlsbad, CA, USA). All labeling procedures were
performed according to the manufacturers’ protocols. Micro-
array experiments were conducted using HumanHT-12 v4
Sentrix Expression BeadChips (Illumina). Hybridization of
labeled cRNA to the BeadChip, washing and scanning were
performed according to the Illumina Bead Station 5003
instructions. Raw data were extracted using the software pro-
vided by the manufacturer (Illumina GenomeStudio v2011.1
[Gene Expression Module v1.9.0]). The local-pooled-error
(LPE) test was used to determine the statistical signiﬁcance
of differences in expression data, and the false-discovery rate
was controlled for given p-values using the Benjamini–Hoch-
berg algorithm. Microarray data are deposited in Gene
Expression Omnibus (GEO) with the accession number:
GSE89673.
The private accession link:
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token5qb
ypgquqtfsxnyb&acc5GSE89673)
Results
MiR-494 downregulates genes involved in the cell cycle
and cell cycle-related pathways
We compared the downregulation efﬁciency of the three pre-
viously reported KIT mRNA targeting microRNAs (miR-221,
miR-193a and miR-494) in GIST cell lines. Western blot
analyses were performed using GIST430 and GIST882 cells
treated with the three microRNAs. MiR-494 was the only
microRNA that induced signiﬁcant downregulation of KIT in
both GIST430 and GIST882 cells (Fig. 1a). This result was
consistent with the results of a previous study.20 To identify
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the additional genes affected by miR-494, we performed
mRNA expression analysis using two groups each of
GIST430 and GIST882 cells, with or without miR-494 treat-
ment. Each group of cells was transfected with siNC or miR-
494 and was harvested after 72 hr. The samples of extracted
RNA were then subjected to DNA microarray analysis.
The DNA microarray data were used for gene ontology and
pathway analysis. A total of 443 genes that were downregulated
>1.2-fold in both GIST430 and GIST882 cells were initially
selected (Fig. 1b). Pathway analysis of the selected genes (using
DAVID software) revealed that the cell cycle and cell cycle-
related pathways were the most signiﬁcantly affected by miR-
494 treatment (Supporting Information Table S2). This result
indicated that inhibition of GISTs by miR-494 treatment was
mainly mediated through perturbation of the cell cycle. The
genes in the two cell lines that were affected by miR-494 were
categorized into nine expression patterns (Fig. 1c); no signiﬁ-
cant pathway alterations were identiﬁed in clusters 2–9 (data
not shown). Genes (cluster 1) involved in the cell cycle and cell
cycle-related pathways were further selected (n5 124). Thirty-
eight of the 124 genes had miR-494 binding sites expected by
TargetScan (Fig. 1b). We further performed gene ontology
analysis using an initial selection of 443 genes (>1.2-fold
downregulation) with cytoscape and found that the cell cycle
relevant categories were mostly changed by miR-494
(p5 5.00E-2, yellow; p5 5.00E-7, orange). Other milder
changes (e.g., in protein metabolism & modiﬁcation, immune
system development & hemopoiesis and metabolic process &
cellular response to stress) were also identiﬁed (Fig. 1d). We
then validated the microarray results by performing qPCR
Figure 1. Cell cycle relevant pathways and genes were commonly downregulated by miR-494. (a) Downregulation of KIT expression by miR-
221, miR-193a and miR-494 was measured using western blot analysis in GIST430 and GIST882 cells. (b) A scheme for identifying path-
ways and genes significantly affected by miR-494 treatment in GIST430 and GIST882 cells. The selected genes were subjected to gene
ontology analysis using DAVID software. (c) The nine gene expresson patterns found in GIST430 and GIST882 cells after miR-494 treatment.
(d) Gene ontology network clusters were generated (Cytoscape software) using the genes commonly downregulated by miR-494 in GIST430
and GIST882 cells (443 genes, >1.2-fold downregulation). The significance of enrichment of the corresponding gene ontology is repre-
sented by node intensity (p55.00E-2, yellow; p55.00E-7, orange); the number of genes is represented by node size.
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analysis of six randomly selected genes. Downregulation of the
mRNA expression level of each gene was detected with approx-
imately similar results in both the qPCR analysis and the
microarray analysis. This result indicated that the results of the
microarray data were valid (Supporting Information Fig. S1).
Survivin, a cell cycle regulator, is a novel target gene of
miR-494 in GISTs
We also aimed to identify novel non-KIT genes regulated by
miR-494 in GISTs. Based on their reported cancer relevance,
we selected CKS1B, DNMT3B, FOXM1 and survivin from the
list of the cell cycle-related genes with miR-494 binding sites
(n5 38); (Fig. 2a). FOXM1 is a transcriptional activator
involved in cell proliferation. FOXM1 regulates cell cycle-
related genes.29 DNMT3B is a de novo methyltransferase
required for the survival of cancer cells.30 CKS1B is a regula-
tor that binds to the cyclin-dependent kinases, which pro-
motes G2 to M phase transition.31 Survivin is also a cell cycle
regulator involved in mitosis and has potential clinical signiﬁ-
cance in GIST tumorigenesis.32,33 To validate whether these
genes were directly regulated by miR-494, reporter vectors
were constructed by conjugating each TargetScan-predicted
miR-494 binding site located in the 30-UTR regions of each
gene with a luciferase expression vector (Fig. 2b). Reporter
assays were performed using HeLa cells transfected with each
reporter vector and miR-494. MiR-494 inhibitor treatment
was included in each assay to conﬁrm that inhibition of
endogenous miR-494 rescues luciferase activity. The reporter
assays revealed that luciferase activity from the FOXM1 or
DNMT3B reporters was barely changed by the miR-494 or
miR-494 inhibitor, while Luciferase activity from CKS1B and
survivin reporters was slightly and signiﬁcantly decreased by
miR-494 and increased by the miR-494 inhibitor, respectively
(Fig. 2c).
To further validate the reporter assay results, we generated
additional mutant CKS1B and survivin reporter vectors by
substituting miR-494 site seed sequences with random nucle-
otide sequences (GTTT to CCGG). In subsequent reporter
assays, the decrease in luciferase activity following miR-494
treatment was fully rescued in samples with the survivin
mutant vector, but only a slight increase in luciferase activity
was observed in samples with the CKS1B mutant vector (Fig.
2d). We therefore found that survivin is a direct and critical
target of miR-494 in GISTs. To further demonstrate this
ﬁnding, we constructed survivin expression vectors with and
without the 30-UTR to conﬁrm miR-494-mediated downregu-
lation of survivin expression (Supporting Information Fig.
S2a). Western blotting analysis showed that miR-494 treat-
ment caused a substantial decrease in survivin expression in
cells transfected with the 30-UTR containing the survivin
expression vector; however, no change in survivin expression
was observed in cells transfected with the survivin expression
vector lacking the 30-UTR (Supporting Information Figs. S2b
and S2c).
Next, CKS1B, survivin and miR-494 expression in
GIST430 and GIST882 cells was assessed. As GISTs express
miR-494 at very low levels, high levels of survivin and
CKS1B expression were expected.16 Western blot analyses
revealed only low-level expression of CKS1B, whereas survi-
vin was expressed at high levels (Fig. 2e). Further analysis of
miR-494 expression conﬁrmed the inverse relationship
between miR-494 and survivin expression in GIST430 and
GIST882 cells (Fig. 2f).
Based on a report indicating that survivin expression
decreases upon KIT inhibition, we investigated whether miR-
494 represses survivin expression independent of KIT.33 As
previously reported, RNAi-mediated KIT depletion induces a
signiﬁcant decrease in survivin expression, which is almost
completely rescued by KIT overexpression. Notably, we
found that the decrease in survivin expression following KIT
depletion by miR-494 treatment was not rescued, which sug-
gests that miR-494 independently downregulates survivin
expression irrespective of changes in KIT expression
(Supporting Information Fig. S2d).
Survivin expression is inversely correlated with miR-494
expression in GIST tissues
After we found that survivin mRNA is a direct target of
miR-494, we examined the relationships in expression
between survivin and miR-494 in human GIST tissues. We
measured miR-494 expression using Taqman-based micro-
RNA qPCR and survivin expression, and western blot analy-
sis, in 35 GIST tissues. KIT expression was also measured to
conﬁrm the previously reported inverse correlation between
miR-494 and KIT in GISTs (Fig. 3a).20 Levels of KIT and
survivin expression were normalized to GAPDH expression,
and miR-494 expression was normalized to that of RNU6B.
The resulting normalized expression data were log–log con-
verted for subsequent statistical analyses (Supporting Infor-
mation Fig. S3). The correlation analysis revealed that KIT
expression was inversely correlated with miR-494 expression
in the 35 GIST tissues (Pearson’s correlation coefﬁcient,
r520.450, p5 0.007) (Fig. 3b). MiR-494 expression was
inversely correlated with survivin expression (Pearson’s corre-
lation coefﬁcient, r520.418, p5 0.012) (Fig. 3c). A tendency
toward a positive correlation was also found for KIT and sur-
vivin expression, but this result was not statistically signiﬁ-
cant (Pearson’s correlation coefﬁcient, r5 0.267, p5 0.120)
(Fig. 3d). This lack of statistical signiﬁcance may be due to
the additional factors (e.g., ETV1 and PKC-u) that can affect
KIT expression.28,34
Inhibition of survivin leads to G2/M phase arrest and
subsequent apoptosis, accompanying perturbation of the
PI3K-AKT pathway
To investigate the biological signiﬁcance of survivin in GISTs,
we performed a proliferation assay using GIST430 and
GIST882 cells transfected with siNC, miR-494 or siSurvivin.
siSurvivin was included to determine whether KIT-independent
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Figure 2. MiR-494 directly regulates survivin, which is universally overexpressed in GIST cells. (a) Putative novel miR-494 target genes were
selected (CKS1B, survivin, DNMT3B and FOXM1) based on previous reports and cancer relevance. Survivin was selected after target valida-
tion assay, and endogenous protein expression level, results. (b, c) The reporter vector was constructed by conjugating Renilla luciferase
with a Target-Scan predicted miR-494 binding site in each 30-UTR of CKS1B, survivin, DNMT3B and FOXM1. Each reporter vector with siNC,
miR-494 or miR-494 inhibitor was transfected into HeLa cells. Dual luciferase assays were performed by measuring Renilla and Firefly lucif-
erase activity at 48 hr post-transfection. (d) Mutant reporter vectors for CKS1B and survivin were further constructed by substituting seed
match sequences of miR-494 (GTTT->CCGG). After transfection of the wild-type reporter vector (WT) and mutant reporter vector (Mt) with
siNC or miR-494, a dual luciferase assay was performed. WT denotes the wild-type vector with the orginal binding site of miR-494. Mt
denotes the mutant vector with a mutated binding site of mR-494. To determine the relative luciferase activity, the Renilla luciferase activity
was normalized based on the Firefly luciferase activity. (e, f) Endogenous survivin, CKS1B and miR-494 expression analyzed by western
blotting and qPCR analysis, respectively, in GIST430 and GIST882 cells.
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survivin downregulation resulted in the inhibition of GIST cells.
The GIST cells were counted and harvested at 3- and 5-day
post-transfection. Western blot analysis was performed to eval-
uate the knock-down efﬁciency of microRNA and RNAi. We
found that miR-494 treatment efﬁciently inhibited proliferation
of the GIST430 and GIST882 cells, with concomitant downre-
gulation of KIT and survivin. The similar pattern of prolifera-
tion inhibition was observed when survivin was depleted by
siRNA (Fig. 4a). FACS analysis of the cell cycle after miR-494
or siSurvivin treatment revealed that miR-494 induced a slight
increase (5.9% in GIST430 and 4.7% in GIST882 cells) in the
G0–G1 phase and a decrease (2.5% in GIST430 and 0.6% in
GIST882 cells) in the S phase. Survivin knock-down induced
substantial increases (26.1% in GIST430 and 27.9% in GIST882
cells) in the G2-M phase and substantial decreases (27.9% in
GIST430 and 30.9% in GIST882 cells) in the G0–G1 phase (Fig.
4b). Subsequent apoptosis analysis revealed that early and late
apoptosis were signiﬁcantly induced in both GIST cell lines by
miR-494 (19.9% in GIST430 and 16.6% in GIST882 cells) and
by siSurvivin (22.5% in GIST430 and 30.8% in GIST882 cells)
(Fig. 4c). MiR-494- and siSurvivin-mediated GIST inhibition
was further revealed by the colony formation assay. Two weeks
after transfection of miR-494 or siSurvivin into each cell line,
colonies with >50 cells were counted. Colony numbers were
markedly reduced by miR-494 (73.2% in GIST430 and 51.3% in
GIST882 cells) or siSurvivin (97.3% in GIST430 and 96.9% in
GIST882 cells) treatment (Fig. 4d). Overall, KIT-independent
downregulation of survivin was sufﬁcient to inhibit GISTs, with
accompanying dramatic cell cycle arrest and cell death.
In addition to survivin’s roles during the cell cycle pro-
cess, it is also an effector molecule belonging to the mTOR
pathway, which is a subpathway of the PI3K-AKT path-
way.35,36 Therefore, we examined whether inhibition of survi-
vin would affect the PI3K-AKT pathway in GISTs. The levels
of the activated forms of AKT, ERK and STAT3 were mea-
sured after miR-494 or siSurvivin treatment in GIST430 and
GIST882 cells. MiR-494 and siSurvivin treatment induced
slight decreases in phospho-STAT3 and substantial decreases
in phospho-AKT. The phospho-ERK levels were not changed
by exposure to miR-494 or siSurvivin (Fig. 5a). To further
examine the signiﬁcance of the PI3K pathway in GISTs,
GIST cells were exposed to speciﬁc kinase inhibitors against
MEK (PD0325901), PI3K (ZSTK474) or AKT (MK-2206)
and proliferation assays were performed. The proliferation
assay revealed that the inhibitor against the PI3K pathway
signiﬁcantly blocked GIST proliferation; inhibitors against the
MEK or AKT pathways were less, or were not, effective
(Fig. 5b). Alteration of downstream signaling molecules after
treatment with PI3K, AKT or MEK inhibitors was also ana-
lyzed using western blot. Prolonged treatment with inhibitors
against AKT and PI3K induced dramatic downregulation of
survivin; the inhibitor against MEK barely affected survivin
Figure 3. Relationships between the expression of survivin, miR-494 and KIT in 35 GIST tissues. (a) The expression levels of KIT, P-KIT, sur-
vivin and GAPDH were mesured in 35 GIST tissues using western blot analysis. (b–d) Statistical correlation analysis was performed for the
expression of KIT and miR-494 (Pearson’s correlation coefficient, r520.450, p50.007), the expression of survivin and miR-494 (Pearson’s
correlation coefficient, r520.418, p50.012) and the expression of KIT and survivin (Pearson’s correlation coefficient, r50.267,
p50.120).
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(Fig. 5c). These ﬁndings veriﬁed the signiﬁcance of the PI3K
pathway in GISTs. The results also indicated that survivin
was regulated by the PI3K-AKT pathway and inversely regu-
lated the PI3K-AKT pathway.
Overexpression of survivin relieves miR-494-mediated GIST
inhibition
We next evaluated whether survivin overexpression could
overcome the miR-494-mediated inhibition of GIST cells. A
proliferation assay was performed using GIST cells trans-
fected with miR-494 only or with miR-494 with the survivin
expression vector. The cells were counted at days 3 and 5
after transfection. We found that the ﬂoating dead cells and
cells with abnormal morphology caused by miR-494 were
rarely observed when survivin was overexpressed in the GIST
cells (Supporting Information Fig. S4). The proliferation
assay revealed that miR-494-mediated GIST inhibition was
substantially rescued by survivin overexpression in the
GIST430 and GIST882 cells (Fig. 5d). Constant downregula-
tion of survivin by miR-494 and the restored expression of
survivin by the survivin expression vector were conﬁrmed by
western blot analysis (Fig. 5e). Therefore, combined inhibi-
tion of survivin and KIT would be a more effective approach
for a GIST subtype expressing KIT and survivin.
Figure 4. Downregulation of survivin inhibits proliferation of GIST cells via the perturbation of the cell cycle. (a) Proliferation of GIST430 and
GIST882 cells after exposure to miR-494 or siSurvivin was measured by manually counting cells at 3- and 5-day post-exposure. Knock-
down efficiency of miR-494 and survivin was confirmed using western blot analysis of KIT and survivin. (b, c) Cell-cycle (propidium iodide
staining) and apoptosis (Anexin and propidium iodide staining) analysis in GIST430 and GIST882 cells were performed after exposure to
miR-494 or siSurvivin. (d) Colony formation of GIST430 and GIST882 cells was evaluated after miR-494 or siSurvivin treatment. Two weeks
after seeding 40,000 cells of GIST430 and GIST882, colonies were stained using crystal violet and were counted using a Colony V1.1.
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Figure 5. Downregulation of survivin induced the inhibition of the PI3K-AKT pathway and overexpression of survivin rescued miR-494-
mediated GIST inhibition. (a) The expression of KIT, p-KIT, AKT, p-AKT, p-STAT3, STAT3, p-ERK, ERK and survivin in GIST430 and GIST882
was measured after treatment with siNC, miR-494 or siSurvivin. (b) The inhibitory effect on GIST430 and GIST882 cells was evaluated by
comparing proliferation of GIST cells with or without treatment with specific inhibitors against MEK (PD0325901, 100 nM), PI3K (ZSTK474,
10 lm) or AKT (MK-2206, 5 lm). Cells were counted at 2 days, 4 days and 6 days after inhibitor treatment. (c) The changes in expression
of p-KIT, KIT, p-AKT, AKT, p-ERK and ERK, and survivin, were measured using western blot analysis performed after time-course treatment
with each inhibitor. (d) The cell numbers were normalized to the control cell numbers and presented as relative values. (e) The rescued
expression of survivin by transfection of the survivin expression vector with miR-494 was confirmed using western blot analysis.
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Survivin is mainly localized in the nucleus and regulates
KIT mRNA expression by binding the promoter region of
KIT
When survivin expression was manipulated by transfecting
the survivin expression vector or siSurvivin, we found that
KIT protein expression changed in response (Figs. 4a, 5a and
5e). We therefore hypothesized that survivin might regulate
KIT expression, possibly at the mRNA or protein level, or
both. To investigate how survivin regulated KIT expression,
the localization of KIT and survivin was analyzed using
immunoﬂuorescence microscopic and immunohistochemistry
examination in GIST cells and tissues. As previously
reported, KIT showed perinuclear localization, which repre-
sented its retention in the Golgi complex.28 However, survi-
vin was detected in the nucleus. These results indicated that
there was limited direct interaction between KIT and survi-
vin. Because survivin was only detected in the nucleus, we
suspected that survivin might regulate KIT expression at the
transcription level (Fig. 6a). Thus, we measured the mRNA
and protein expression of KIT in GIST cells after transfection
of the survivin expression vector or siSurvivin. Western blot
analysis revealed that induced overexpression of survivin
resulted in a gradual increase in KIT expression in both
GIST430 and GIST882 cells (Fig. 6b). The results of the
qPCR analysis indicated that the KIT mRNA expression sim-
ilarly increased along with the gradual increase in KIT
expression (Fig. 6c). Moreover, siRNA-mediated downregula-
tion of survivin induced a signiﬁcant decrease in KIT mRNA
expression, and a subsequent reduction in KIT protein
expression, in both GIST cell lines (Figs. 6d and 6e).
We also investigated changes in KIT mRNA and protein
expression after survivin downregulation/overexpression in
two colon cancer cell lines (DLD-1 and Colo320DM) that
express wild-type KIT. Western blot and qPCR analyses
showed that downregulation of survivin induced decreases in
KIT mRNA and protein levels in both cell lines (Supporting
Information Figs. S5a and S5b), whereas overexpression of
survivin resulted in increased KIT mRNA and protein
expression (Supporting Information Figs. S5c and S5d). These
ﬁndings allowed us to suspect the putative roles for survivin
as a transcription regulator for KIT. To test survivin protein
interact with which promoter region of KIT, reporter vectors
containing the promoter regions of KIT were generated. We
divided the promoter region (2 Kb) of KIT into four frag-
ments by calculating the expected score of transcription fac-
tor binding obtained from a bioinformatic software program
(MethPrimer). Each reporter vector was transfected into
HeLa cells with the survivin expression vector and was har-
vested to measure luciferase activity. We found that com-
pared to the control, the vector containing fragment 3 (2329
to 1155, the ﬂanking region of exon 1) had a dramatic
increase in luciferase activity in response to the survivin over-
expression (>20-fold); no signiﬁcant increases in luciferase
activity occurred in the vectors containing the other frag-
ments (Fig. 6f).
A ChiP assay was conducted to further conﬁrm the direct
interaction between survivin and the KIT promoter fragment
3 regions. Chromatin samples were incubated with anti-
survivin antibody, anti-histone H3 antibody (positive control)
and IgG (negative control). Semi-qPCR analysis using the
isolated chromatin samples showed that the ﬂanking region
of exon 1 (247 to 1123) was most signiﬁcantly enriched by
ChiP. These ﬁndings were consistent with the reporter assay
results (Figs. 6g and 6h) and indicate that survivin directly
binds to the KIT promoter region, enhancing the transcrip-
tional activity of KIT.
The expression of MiR-494 and survivin is related to the
poor clinical outcome of GIST patients
We evaluated the clinical behavior of GISTs according to sur-
vivin expression by performing immunohistochemistry for
survivin using 113 GISTs. Survivin expression was catego-
rized as a strong (n5 8), moderate (n5 49) or weak (n5 56)
response (Supporting Information Fig. S6a). Kaplan–Meier
survival analysis revealed that the patients with strong
expression of survivin had poor overall survival (p5 0.004)
(Supporting Information Fig. S6b). We further analyzed the
relationships between survivin expression and the clinical
parameters, depending on the mutation status of KIT in 113
GISTs. Survivin expression was closely related to mitotic
index (p5 0.013), tumor size (p5 0.018) and poor patient
survival (p5 0.016) in a cohort of GIST patients with the
KIT mutation (n5 93) (Supporting Information Table S3).
Multivariate analysis indicated that strong expression of sur-
vivin (p5 0.025) was a predictive factor for the poor patient
survival (Supporting Information Table S4).
The relationship between miR-494 expression and clinical
characteristics of tumors was analyzed relative to miR-494
expression in the 35 GISTs described in Figure 3. Due to the
lack of follow-up data for 1 patient, data for only 34 of the
GISTs were statistically analyzed. The 34 cases were classiﬁed
as strong (n5 8), moderate (n5 18) or weak (n5 8) miR-
494 expression. Statistical analyses showed correlations
between miR-494 expression and tumor size (p5 0.001),
mitotic index (p5 0.024), grade (p5 0.003) and survival
(p5 0.013) (Supporting Information Table S5). Kaplan–Meier
analysis of the data revealed that patients expressing weak
levels of miR-494 had poorer overall survival (p5 0.017)
(Supporting Information Fig. S7). However, multivariate
analysis of the 34 GIST cases revealed no signiﬁcant predic-
tive factors for survival or recurrence/metastasis (Supporting
Information Table S6).
Discussion
Progression on imatinib in metastatic patients with GIST is
associated with a mostly dismal outcome and salvage thera-
pies have failed to overcome resistance.10,11 ATP-competitive
inhibitors of KIT are unlikely to inhibit the full spectrum of
resistance mutations and therefore alternative measure might
be useful to inhibit oncogenic KIT signaling. A number of
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Figure 6. Survivin binds to a specific region of the KIT promoter and induces KIT expression at the transcription level. (a) The localization of KIT and
survivin was examined using GIST430 andGIST882 cells and immunofluorescencemicroscopic analysis (left panel). The nuclear localization of survi-
vin was examined by immunohistochemistry in a representative GIST tissue (right panel). (b, c) The changes in expression of KITmRNA and protein
were evaluated using qPCR and western blot in GIST430 and GIST882 cells transfected with gradually increasing amount of survivin plasmids. (d, e)
Expression of KITmRNA and protein weremeasured after siSurvivin treatment. (f) Tomap a specific region of KIT promoter bound by survivin, various
KIT promoter fragments conjugatedwith Firefly luciferase (five different fragments, including the full-length promoter) were constructed, and dual
luciferase assay was performed 48 hr after tranfection of each construct with survivin expression vector into HeLa cells. The schematic map of the
vectors is presented on the left panel and the relative luciferase activity results are presented on the right panel. The KIT promoter region was
obtained from bioinformatic software (MethPrimer). To determine the relative luciferase activity, the Firefly luciferase activity was normalized based
on the Renilla luciferase activity. (g) Chromatin immunoprecipitation assay performed using anti-survivin, anti-histone H3 and normal rabbit igG anti-
bodies. (h) Enrichment of the survivin-binding DNA fragment in the KIT promoter region was evaluated by semi-qPCR. In the positive control sample,
binding of histone H3 to RPL30 exon 3was evaluated (left panel). Densitometric analysis of the intensity of semi-qPCR assay bands (right panel).
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investigators have tried to improve delivery of conventional
drugs, and develop a new generation of drugs that include
small RNA-based therapeutic tools. Deacetylase inhibitors
have previously been shown to downregulate KIT both by
transcriptional repression and by HSP90-mediated degrada-
tion with evidence of clinical activity.37,38 One of the break-
throughs in GIST inhibition has been the identiﬁcation of
microRNAs showing inverse correlation with KIT expression
in GISTs.17,19–21
The gene ontology analyses using microarray data revealed
that the pathways affected by miR-494 were mostly relevant
to the cell cycle. This result suggested that miR-494 speciﬁ-
cally targeted a group of cell cycle relevant genes. Concomi-
tant regulation of cell cycle relevant genes by miR-494 led to
the arrest of the overall cell cycle, and eventual cell death.
These ﬁndings were consistent with the results of studies that
some genes targeted by a speciﬁc microRNA tend to be func-
tionally linked; altered expression of a single microRNA
might cause severe effects on a speciﬁc cellular pathway.22
Among the cell cycle relevant genes identiﬁed in our study,
survivin is of particular interest because it is involved in the
AKT-mTOR pathway, which is critical for GIST tumorigene-
sis and therapy.6,36 Upregulation of survivin disturbs the
anti-cancer effects of several inhibitors against upstream mol-
ecules involved in the IGFR/PI3K/AKT/mTOR pathway in
hepatocellular carcinoma.35 However, a complete understand-
ing of the details of the roles of survivin in GISTs has not
been elucidated. In our study, we found that survivin mRNA
was a direct target of miR-494 and that survivin expression
was inversely correlated with miR-494 expression. Evaluation
of cell proliferation, the cell cycle, apoptosis and colony for-
mation, also revealed that downregulation of survivin was
sufﬁcient to inhibit GISTs without manipulation of KIT. We
also found that survivin overexpression rescued miR-494-
mediated GIST inhibition. These ﬁndings suggest that survi-
vin has critical roles in GISTs and is as important a target of
miR-494 as KIT is, for GIST inhibition.
Survivin has various roles depending on its location in the
cell. Nuclear survivin binds to the mitosis promoting com-
plex and induces cell cycle progression.32 Mitochondrial sur-
vivin reportedly binds directly to caspases 3 and 7, inhibiting
the caspase-mediated cascade leading to apoptosis.39,40 The
observation that survivin also functions as a downstream
effector in the PI3K-AKT pathway also suggests it inhibits
apoptosis.35 However, some studies have reported controver-
sial ﬁndings suggesting that the apoptosis-inhibiting role of
survivin varies with different types of cancer.41,42 The survi-
vin gene was recently identiﬁed as essential for survival of
GISTs in a synthetic lethality screen; YM155-mediated survi-
vin inhibition leads to strong apoptosis induction.33 Consid-
ering these reports in conjunction with our ﬁnding that
survivin depletion signiﬁcantly inhibits GIST cell proliferation
and promotes apoptosis in GIST cells, we hypothesize that
survivin, particularly its anti-apoptotic effect, plays an
important role in GIST tumorigenesis and therefore warrants
further characterization.
In our study, survivin was detected only in the nucleus,
and manipulation of survivin resulted in signiﬁcant changes
in KIT expression. Using overexpression and downregulation
of survivin in GIST and colon cancer cell lines, we found
that KIT mRNA expression was regulated by survivin. Sp1,
GATA and SCL have been identiﬁed as transcriptional regu-
lators of KIT in mast cells and hemopoietic cells; only ETV1
has been reported to regulate KIT expression at the transcrip-
tion level in GIST cells.34,43,44 To our knowledge, this is the
ﬁrst study to ﬁnd that survivin is a transcriptional regulator
of KIT. Survivin directly interacted with the promoter region
near exon 1 of KIT and upregulated KIT mRNA expression.
These ﬁndings indicate that (1) survivin is a novel transcrip-
tional regulator of KIT, and (2) the two target genes of miR-
494, KIT and survivin, form an activation loop that contrib-
utes to GIST progression.
Sustained activation of KIT leads to the hyperactivation of
the MAPK, PI3K and JAK/STAT pathways.6,45 However, pre-
clinical studies have found that inhibiting the PI3K/AKT/
mTOR pathway is a rational method to overcome the resis-
tance associated with prolonged treatment.6,46,47 Consistent
with previous study results, we found that the inhibitor
against the PI3K pathway had most potent and long-term
inhibitory effect on GIST proliferation. However, many stud-
ies have also found that single molecule targeting cancer
treatment is challenging due to the compensatory activation
of other molecules belonging to the same pathway. For exam-
ple, targeting a single effector molecule belonging to the
EGFR-Ras-Raf-MEK-ERK pathway almost always leads to
drug resistance in colon cancers.48 In addition, compensatory
activation between the PI3K pathway and the mTOR path-
way has also been reported in prostate and breast cancer cell
lines.49
Several studies have suggested the use of combined thera-
peutic approaches based on the idea that targeting multiple
effector molecules enhances the therapeutic effects of anti-
cancer agents. Zhu et al. demonstrated that combined use of
miR-494 and RNAi targeting survivin synergistically and
markedly inhibit the growth of prostate cancer cells.50 The
vertical blockade combined therapeutic approach targets
effector molecules within the same signaling pathway, leading
to potent and prolonged inhibition of cancer cell growth. Sin-
gle microRNAs that target genes belonging to functionally
linked groups are potentially ideal vertical blockade agents.22
Our ﬁndings that KIT and survivin are functionally linked
targets of regulation by miR-494 or the PI3K pathway in
GISTs suggest that miR-494 could be used as a novel vertical
blockade agent for treating GISTs (Supporting Information
Fig. S8).
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